Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-04
2010-06-29
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000, C544S127000, C544S162000, C544S128000, C546S122000, C548S491000
Reexamination Certificate
active
07745451
ABSTRACT:
Fused heterocyclic compounds are disclosed that have formula 1:where A, B, L, N, R1, R3, R4′, Y and Z are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
REFERENCES:
patent: 3248395 (1966-04-01), Ohnacker
patent: 3424760 (1969-01-01), Helsley et al.
patent: 3424761 (1969-01-01), Helsley et al.
patent: 7022849 (2006-04-01), Pitts et al.
patent: 7105667 (2006-09-01), Pitts et al.
patent: 7232833 (2007-06-01), Bigot et al.
patent: 2003/0092908 (2003-05-01), Pitts
patent: 2005/0049253 (2005-03-01), Tegley
patent: 2006/0239999 (2006-10-01), Saki et al.
patent: 2006/0252679 (2006-11-01), Saki et al.
patent: 2007/0037834 (2007-02-01), Arai et al.
patent: 2007/0135458 (2007-06-01), Chen et al.
patent: 2007/0142402 (2007-06-01), Ding et al.
patent: 2502588 (1976-07-01), None
patent: 1033384 (1966-06-01), None
patent: 04224580 (1992-08-01), None
patent: 2005162673 (2005-06-01), None
patent: WO 00/69849 (2000-11-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 01/44246 (2001-06-01), None
patent: WO 01/62737 (2001-08-01), None
patent: WO 02/08221 (2002-03-01), None
patent: WO 02/22601 (2002-03-01), None
patent: WO 02/22602 (2002-03-01), None
patent: WO 02/22603 (2002-03-01), None
patent: WO 02/22604 (2002-03-01), None
patent: WO 02/22605 (2002-03-01), None
patent: WO 02/22606 (2002-03-01), None
patent: WO 02/22607 (2002-03-01), None
patent: WO 02/22608 (2002-03-01), None
patent: WO 02/50065 (2002-06-01), None
patent: WO 02/053558 (2002-07-01), None
patent: WO 02/057259 (2002-07-01), None
patent: WO 02/059111 (2002-08-01), None
patent: WO 02/062789 (2002-08-01), None
patent: WO 02/087513 (2002-11-01), None
patent: WO 03/062225 (2003-07-01), None
patent: WO 03/076427 (2003-09-01), None
patent: WO 03/104230 (2003-12-01), None
patent: WO 2004/041259 (2004-05-01), None
patent: WO 2004/056774 (2004-07-01), None
patent: WO 2004/087056 (2004-10-01), None
patent: WO 2004/093912 (2004-11-01), None
patent: WO 2005/049033 (2005-06-01), None
patent: WO 2006/035061 (2006-04-01), None
patent: WO 2007/070872 (2007-06-01), None
Cockayne, et al., J. Physiol., vol. 567, No. 2, 621-639, Sep. 1, 2005.
Raff, et al., Europ. Urology 48 (2005) 303-308.
Galligan, et al., Brit. J. Pharmacol. (2004) 141, 1294-1302.
Florenzano, et al., Brain Repair, Chapter 5, 2006, 77-100.
Willart, et al., Clin. & Experim. Allergy, 39, 12-29 (2008).
Francis et al., “Anxiolytic Properties of Certain Annelated [1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-ones,” Journal of Medicinal Chemistry, 34(9):2899-2906 (1991).
Bennett and Xie, 1988, “A Peripheral Mononeuropathy in Rat that Produces Disorders of Pain Sensation Like Those Seen in Man”,Pain, 33:87-107.
Chaplan et al., 1994, “Quantitative Assessment of Tactile Allodynia in the Rat Paw,”J. Neurosci. Methods, 53:55-63.
Cockayne et al., 2000, “Urinary Bladder Hyporeflexia and Reduced Pain-Related Behaviour in P2X3-Deficient Mice,”Nature, 407:1011-1015.
Cockayne et al. 2005, “Urinary Bladder Hyporeflexia and Reduced Pain-Related Behaviour in P2X3-Deficient Mice,”J. Physiol., 567:621-639.
Dixon, 1980, “Efficient Analysis of Experimental Observations,”Ann. Rev. Pharmacol. Toxicol., 2:441-462.
Dmitrieva et al., 1997, “The Role of Nerve Growth Factor in a Model of Visceral Inflammation,”Neuroscience, 78:449-59.
Dubuisson and Dennis, 1977, “The Formalin Test: a Quantitative Study of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats,”Pain, 4:161-174.
Jarvis et al., 2004, “[3H]A-317491, A Novel High-Affinity Non-Nucleotide Antagonist that Specifically Labels Human P2X2/3 and P2X3 Receptors,”J. Pharmacol. Exp. Ther., 10:407-416.
Hargrreaves et al., 1988, “A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia,”Pain, 32:77-88.
Kawashima et al., 1998, “A Novel and Efficient Method for the Stable Expression of Heteromeric Ion Channels in Mammalian Cells,”Receptors Channels, 5:53-60.
Kim and Chung, 1992, “An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat,”Pain, 50:355-363.
Kotinen et al.,1999, “Behavioural Measures of Depression and Anxiety in Rats with Spinal Nerve Ligation-Induced Neuropathy,”Pain, 80:341-346.
Neelands et al., 2003, “2′, 3′-O-(2,4,6,trinitropheny1)-ATP and A-317491 are Competitive Antagonists at a Slowly Desensitizing Chimeric Human P2X3 Receptor,”Br. J. Pharmacol., 140:202-10, 2003.
Polomano et al., 2001, “A Painful Peripheral Neuropathy in the Rat Produced by the Chemotherapeutic Drug, Paclitaxel,”Pain, 94:293-304.
Stein et al. 1988, “Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds,”Pharmacol. Biochem. Behav., 31:451-455.
Vlaskovska et al., 2001, “P2X3 Knock-Out Mice Reveal a Major Sensory Role for Urothelially Released ATP,”J. Neuroscience, 21:5670-5677.
Wesselmann et al., 1998, “Uterine Inflammation as a Noxious Visceral Stimulus: Behavioral Characterization in the Rat,”Neurosci. Lett., 246, 73-76.
Yee, 1997, “In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict in vivo (Small Intestinal) Absorption in Man—Fact or Myth,”Pharm. Res., 14:763-766.
Zhou et al., 1998, “Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature,”Biophys. J., 74:230-241.
ISA/US International Search Report dated Sep. 16, 2008, for International Application No. PCT/US2006/017614.
ISA/US Written Opinion of the International Searching Authority dated Sep. 16, 2008, for International Application No. PCT/US2006/017614.
Kaub Carl J.
Kelly Michael G.
Kincaid John
Jaisle Cecilia M
Klauber & Jackson LLC
Renovis, Inc.
Wilson James O
LandOfFree
Tetrahydronaphthyridine and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydronaphthyridine and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydronaphthyridine and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4225617